Definium Therapeutics schedules Investor and Analyst Day in New York on April 22, 2026, featuring DT120 ODT and updates for GAD and MDD

DT120 ODT (lysergide tartrate) is a core focus of Definium Therapeutics’ Investor & Analyst Day on Wednesday, April 22, 2026 in New York. Definium says the program will include executive leadership and external key opinion leaders discussing the treatment landscape for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with emphasis on clinical and real-world context. Key agenda items include updates and expectations for anticipated 2026 topline data readouts for DT120 ODT in Phase 3 development, along with discussion of potential market opportunity. The event runs 10 AM to 12 PM EDT at Well& by Durst (151 W 42nd St, New York, NY 10036) and offers both in-person (invited analysts and institutional investors) and virtual viewing via a live or archived webcast for at least 30 days.